NASDAQ: RLAY - Relay Therapeutics, Inc.

Yield per half year: -60%
Dividend yield: 0.00%
Sector: Healthcare

Company Analysis Relay Therapeutics, Inc.

Download the report: word Word pdf PDF

1. Summary

Advantages

  • Price (2.96 $) is less than fair price (5.93 $)

Disadvantages

  • Dividends (0%) are below the sector average (0.5467%).
  • The stock's return over the last year (-60.9%) is lower than the sector average (-25.51%).
  • Current debt level 6.33% has increased over 5 years from 6.31%.
  • The company's current efficiency (ROE=-45.47%) is lower than the sector average (ROE=9.01%)

Similar companies

DENTSPLY SIRONA

Alexion

Amgen

ABIOMED

2. Share price and performance

2.1. Share price

2.2. News

No news yet

2.3. Market efficiency

Relay Therapeutics, Inc. Healthcare Index
7 days -11.4% -20.9% -2%
90 days -30% -25.3% -12.1%
1 year -60.9% -25.5% 6.4%

RLAY vs Sector: Relay Therapeutics, Inc. has significantly underperformed the "Healthcare" sector by -35.39% over the past year.

RLAY vs Market: Relay Therapeutics, Inc. has significantly underperformed the market by -67.27% over the past year.

Stable price: RLAY is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: RLAY with weekly volatility of -1.17% over the past year.

3. Summary of the report

3.1. General

P/E: 17.31
P/S: 55.08

3.2. Revenue

EPS -2.79
ROE -45.47%
ROA -40.52%
ROIC -47.5%
Ebitda margin -1489.76%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Below fair price: The current price (2.96 $) is lower than the fair price (5.93 $).

Price significantly below the fair price: The current price (2.96 $) is 100.3% lower than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (17.31) is lower than that of the sector as a whole (57.09).

P/E vs Market: The company's P/E (17.31) is lower than that of the market as a whole (48.45).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (1.87) is lower than that of the sector as a whole (4.61).

P/BV vs Market: The company's P/BV (1.87) is lower than that of the market as a whole (3.38).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (55.08) is higher than that of the sector as a whole (33.5).

P/S vs Market: The company's P/S indicator (55.08) is higher than that of the market as a whole (10.23).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (-3.46) is higher than that of the sector as a whole (-19.46).

EV/Ebitda vs Market: The company's EV/Ebitda (-3.46) is lower than that of the market as a whole (15.44).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Rising and has grown by 119.58% over the last 5 years.

Earnings Slowdown: The last year's return (0%) is below the 5-year average return (119.58%).

Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (38.84%).

5.4. ROE

ROE vs Sector: The company's ROE (-45.47%) is lower than that of the sector as a whole (9.01%).

ROE vs Market: The company's ROE (-45.47%) is lower than that of the market as a whole (8.97%).

5.5. ROA

ROA vs Sector: The company's ROA (-40.52%) is lower than that of the sector as a whole (0.0151%).

ROA vs Market: The company's ROA (-40.52%) is lower than that of the market as a whole (6.3%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (-47.5%) is lower than that of the sector as a whole (7.63%).

ROIC vs Market: The company's ROIC (-47.5%) is lower than that of the market as a whole (10.96%).

6. Finance

6.1. Assets and debt

Debt level: (6.33%) is quite low in relation to assets.

Increasing debt: over 5 years, the debt has increased from 6.31% to 6.33%.

Excess of debt: The debt is not covered by net income, percentage -15.63%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '0.5467%.

7.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Selling More insider purchases by 17330.4% over the last 3 months.

8.2. Latest transactions

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Relay Therapeutics, Inc.

9.3. Comments